Chardan Capital Maintains Buy Rating on Ocular Therapeutix
Chardan Capital maintained its Buy rating on Ocular Therapeutix's stock with a price target of $23.00, implying an upside of 215.5% from the Oct 1 close of $7.29.
Chardan Capital maintained its Buy rating on Ocular Therapeutix's stock with a price target of $23.00, implying an upside of 215.5% from the Oct 1 close of $7.29.